ArticleJournal of the American Heart Association2025
Tafamidis Reduces Death and Hospitalization for Acute Heart Failure in Octogenarian Patients With Transthyretin Cardiac Amyloidosis: A Propensity Score-Weighted Cohort Study.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy.Cardiology and therapy · 2026Article
- The Impact of Risk Factors and Comorbidities on Heart Failure in the Aging Population.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransthyretin cardiac amyloidosis results from the deposition of misfolded amyloid fibrils in cardiac tissue, leading to progressive heart failure. Tafamidis, a transthyretin stabilizer, reduces all-cause death and cardiovascular rehospitalization, but its impact on people aged ≥80 years remains underexplored. This study evaluated the effectiveness of tafamidis in octogenarian patients with transthyretin cardiac amyloidosis compared with nonexposed patients.
methodsA propensity score-weighted cohort study included all patients aged ≥80 years with confirmed transthyretin cardiac amyloidosis (hereditary or wild-type) followed at the French Referral Center for cardiac amyloidosis between 2010 and 2021. Patients who initiated tafamidis after November 1, 2018, and were treated for at least 24 months were included in the tafamidis group, whereas patients diagnosed between March 18, 2010, and November 1, 2018, who did not receive tafamidis were included in the nonexposed group. The primary outcome was 24-month all-cause death, and the secondary outcomes were hospital readmission for acute heart failure at 12 months and the causes of death.
resultsBetween March 18, 2010, and July 5, 2021, 465 patients were included. After inverse probability of treatment weighting, tafamidis treatment was found to be associated with a relative reduction of 56% in the 24-month mortality rate (hazard ratio [HR], [95% CI, 0.44 0.35-0.57];
conclusionsTafamidis led to a lower mortality rate and fewer hospital readmissions for acute heart failure in octogenarian patients with transthyretin cardiac amyloidosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.